Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30274
Title: | Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice | Authors: | Etcheberrigaray, René Tan, Mathew DEWACHTER, Ilse Kuipéri, Cuno Van der Auwera, Ingrid Wera, Stefaan Qiao, Lixin Bank, Barry Nelson, Thomas J Kozikowski, Alan P Van Leuven, Fred Alkon, Daniel L |
Issue Date: | 2004 | Publisher: | NATL ACAD SCIENCES | Abstract: | Alzheimer's disease (AD) characteristically presents with early memory loss. Regulation of K(+) channels, calcium homeostasis, and protein kinase C (PKC) activation are molecular events that have been implicated during associative memory which are also altered or defective in AD. PKC is also involved in the processing of the amyloid precursor protein (APP), a central element in AD pathophysiology. In previous studies, we demonstrated that benzolactam (BL), a novel PKC activator, reversed K(+) channels defects and enhanced secretion of APP alpha in AD cells. In this study we present data showing that another PKC activator, bryostatin 1, at subnanomolar concentrations dramatically enhances the secretion of the alpha-secretase product sAPP alpha in fibroblasts from AD patients. We also show that BL significantly increased the amount of sAPP alpha and reduced A beta 40 in the brains of APP[V717I] transgenic mice. In a more recently developed AD double-transgenic mouse, bryostatin was effective in reducing both brain A beta 40 and A beta 42. In addition, bryostatin ameliorated the rate of premature death and improved behavioral outcomes. Collectively, these data corroborate PKC and its activation as a potentially important means of ameliorating AD pathophysiology and perhaps cognitive impairment, thus offering a promising target for drug development. Because bryostatin 1 is devoid of tumor-promoting activity and is undergoing numerous clinical studies for cancer treatment in humans, it might be readily tested in patients as a potential therapeutic agent for Alzheimer's disease. | Keywords: | Alzheimer Disease;Amyloid beta-Protein Precursor;Animals;Benzodiazepinones;Cell Line;Enzyme Activation;Humans;Mice;Mice, Transgenic;Protein Kinase C;Protein Transport;Recombinant Proteins | Document URI: | http://hdl.handle.net/1942/30274 | ISSN: | 0027-8424 | e-ISSN: | 1091-6490 | DOI: | 10.1073/pnas.0403921101 | ISI #: | 000223000200054 | Rights: | 2004 by The National Academy of Sciences of the USA | Category: | A1 | Type: | Research Report |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
11141.full.pdf Restricted Access | Published version | 378.78 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.